July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Development of a Highly Bioavailable Nanocore-based (OcuSurf™) Ophthalmic Formulation for Treatment of Blepharitis
Author Affiliations & Notes
  • Kevin Ward
    Integral BioSystems, Bedford, Massachusetts, United States
  • Koushik Barman
    Integral BioSystems, Bedford, Massachusetts, United States
  • Chinghong Li
    Integral BioSystems, Bedford, Massachusetts, United States
  • Shikha P Barman
    Integral BioSystems, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Kevin Ward, Integral BioSystems (E), Integral BioSystems (P); Koushik Barman, Integral BioSystems (E), Integral BioSystems (P); Chinghong Li, Integral BioSystems (E); Shikha Barman, Integral BioSystems (E), Integral BioSystems (P)
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 230. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kevin Ward, Koushik Barman, Chinghong Li, Shikha P Barman; Development of a Highly Bioavailable Nanocore-based (OcuSurf™) Ophthalmic Formulation for Treatment of Blepharitis
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):230.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Posterior blepharitis is an eyelid disease primarily of the meibomian glands. Bacteria and chronic inflammation are contributing factors for meibomian gland disease, which leads to ocular surface and tear film alterations. Currently, there is no FDA-approved treatment for blepharitis. A membrane-interactive, biphasic, mucoadhesive delivery system, OcuSurf™, derived from “Ocular Surface”, primarily engineered to rapidly permeate ocular tissues was developed. OcuSurf is liquid-crystalline, with dissolved drug entrapped within the nano-cores. We hypothesized that a combination of a steroid and an antimicrobial (Steroid/ Moxifloxacin Free Base) in this delivery system can be co-encapsulated, leading to a highly bioavailable product to treat both anterior and posterior blepharitis. Steroids were evaluated and included fluticasone propionate (FP), dexamethasone (DX) and loteprednol etabonate (LE). FP was selected due to its high potency and its preference for lipophilic tissues (eyelid). Moxifloxacin Free Base (MX) was used instead of its HCl salt for its high lipophilicity. The meibomian glands are located in the deep fenestrations of the eyelids. Thus, a lipid-based delivery system that is designed to “sink” into the inner and outer eyelids immediately upon instillation is ideal. We hypothesize that the OS-FP/MX can be very effective, with a proposed low dose of the steroid (0.01%) to minimize steroid-induced adverse effects (glaucoma, skin) and 0.5% of Moxifloxacin Free Base. We present characterization data: ex-vivo corneal permeability, in-vitro release, in-vivo irritation and pharmacokinetic tear levels with a single installation.

Methods : OS-FP/MX was formulated as per a proprietary process. Permeability studies were performed with freshly excised corneal membranes, using diffusion cells and permeated drug quantitated by HPLC. In-vivo PK studies were performed in rabbit eyes; profiles of FP/MX were collected and analyzed by LC/MS/MS. Irritation assessment of OX-FP/MX was performed in a rabbit model.

Results : The particle size d50 of OS-FP/MX was < 200 nm. High permeation rates of the drug were observed in OS-FP/MX group, in both in-vivo and in-vitro studies. The product was well tolerated in the rabbit eyes.

Conclusions : The rapid release rates both drugs from the nanocores of OS-FP/MX demonstrate feasibility of a highly effective blepharitis product.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×